Skip to main content
Premium Trial:

Request an Annual Quote

NIMH Seeking Collaborators to Develop, Commercialize Protein Quantification Techniques

NEW YORK (GenomeWeb News) – The National Institute of Mental Health’s Laboratory of Neurotoxicology is seeking interested parties to collaborate in a research alliance to develop and commercialize protein quantification techniques using mass spectrometry.
 
NIMH said the technology can be used in basic research, to diagnose disease, or determine amounts of specific marker proteins in heterogeneous mixtures such as blood or urine.
 
The technology, which uses a combination of recombinant DNA technology, fluorescence, proteolytic, and mass spectrometric methods, is currently in the pre-clinical validation phase.
 
Some applications of the technology could include cell signaling, cell cycle function, developing calibration standards for mass spectrometry and non-mass-spectrometric techniques, and in determining post-translation modification of a signature peptide.
 
Investigators interested in finding out more information may view the NIMH announcement here.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.